Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy.
Salvatore PettaFrancesca RiniVincenza CalvarusoCalogero CammàStefania CiminnisiVito Di MarcoEdoardo Giovanni GianniniStefania GrimaudoRosaria Maria PipitoneAntonio CraxìPublished in: Liver international : official journal of the International Association for the Study of the Liver (2019)
In patients with advanced HCV cirrhosis who achieve SVR with DAA, Ʌ ABT assists in assessing the residual likelihood of liver-related events and deaths after viral cure.